<b>ProGRP is a possible tumor marker for patients with Ewing sar</b><b>coma </b>

• YAMAGUCHI Ken

  Shizuoka Cancer Center Hospital Shizuoka Cancer Center Research Institute

• KATAGIRI Hirohisa

  Division of Orthopedic Oncology, Shizuoka Cancer Center Hospital

• TAKAHASHI Mitsuru

  Division of Orthopedic Oncology, Shizuoka Cancer Center Hospital

• ISHIDA Yuji

  Division of Pediatrics, Shizuoka Cancer Center Hospital

• ONO Akira

  Division of Thoracic Oncology, Shizuoka Cancer Center Hospital

• TAKAHASHI Toshiaki

  Division of Thoracic Oncology, Shizuoka Cancer Center Hospital

• OHSHIMA Keiichi

  Medical Genetics Division, Shizuoka Cancer Center Research Institute

• MOCHIZUKI Tohru

  Medical Genetics Division, Shizuoka Cancer Center Research Institute

• URAKAMI Kenichi

  Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute

• MURAMATSU Koji

  Division of Pathology, Shizuoka Cancer Center Hospital

• KAMEYA Toru

  Division of Pathology, Shizuoka Cancer Center Hospital

• ITO Ichiro

  Division of Pathology, Shizuoka Cancer Center Hospital

• NAKAJIMA Takashi

  Division of Pathology, Shizuoka Cancer Center Hospital

Bibliographic Information

Other Title

• ProGRP is a possible tumor marker for patients with Ewing sarcoma

Abstract

We analyzed serum ProGRP levels in patients with Ewing sarcoma, and found that 5 out of 9 patients had elevated levels; the values range equally with those of patients with limited disease of small-cell lung carcinoma. Serum ProGRP levels in patients with bone and soft tissue malignancies other than Ewing sarcoma are not elevated. Immunohistochemical studies demonstrated that ProGRP-like immunoreactivities were detected in Ewing sarcoma tissues obtained from 2 patients with elevated serum ProGRP levels, suggesting that ProGRP is a product of tumor cells of Ewing sarcoma. These results indicate that serum ProGRP could serve as a specific tumor marker for Ewing sarcoma. Since ProGRP is a major hormonal product of tumor cells of small-cell lung carcinoma, a typical neuroendocrine carcinoma, it is reasonable to postulate that the present study provides an evidence for Ewing sarcoma to possess neuroendocrine differentiation.

Journal

• Biomedical Research

  Biomedical Research 36 (4), 273-277, 2015

  Biomedical Research Press

Keywords

• General Biochemistry, Genetics and Molecular Biology
• General Medicine

Details

• CRID: 1390282679879388800
• NII Article ID: 130005094139
• DOI: 10.2220/biomedres.36.273
• ISSN: 1880313X
• ISSN: 03886107
• PubMed: 26299486
• Web Site: https://www.jstage.jst.go.jp/article/biomedres/36/4/36_273/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016128460
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed